Optimizing Care in Atopic Dermatitis: Advanced Practice Provider Insights on Biologic and Systemic Therapies - Episode 3

Topical Treatments in AD

Published on: 

Andrea Nguyen, PA, discusses some of the drawbacks she sees with topical corticosteroid treatment in AD in her practice.

This is a video synopsis/summary of a panel discussion involving Melodie Young, NP, and Andrea Nguyen, PA.

Topical corticosteroids have been a longstanding mainstay in atopic dermatitis (AD) therapy, often prescribed even by primary care providers before patients seek dermatological consultation. However, there are drawbacks associated with prolonged topical steroid use. Many patients may experience "topical fatigue," having tried multiple formulations without sustained relief. The experts note the importance of addressing AD as a chronic disease rather than relying solely on quick relief from corticosteroids.

The conversation explores the drawbacks of topical corticosteroids, emphasizing that they provide temporary relief but do not address the underlying problem of AD. Chronic use can lead to side effects such as skin atrophy, striae, tachyphylaxis, rebound flaring, steroid-induced acne, and pigment changes. The experts advocates for a balanced approach, recommending non-steroidal options for long-term management alongside corticosteroids for acute flares.

Moreover, the discussion delves into the impact of topical corticosteroids on patients with darker skin tones, emphasizing the risk of lighter-colored patches. The time-consuming nature of managing various corticosteroid strengths for different body areas adds complexity to AD treatment.

In conclusion, the dialogue sheds light on the evolving landscape of topical therapies for AD, emphasizing the need for a comprehensive and tailored approach that goes beyond corticosteroids alone.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.